Rosuvastatin for Tocilizumab, an Interleukin-6 Receptor Antibody-induced Dyslipidemia in a Diabetic Patient Complicated With Rheumatoid Arthritis

Hidekatsu Yanai, Hiroshi Kaneko, Yuji Hirowarari

Abstract


Tocilizumab, which blocks interleukin-6 binding to interleukin-6 receptor, is now approved for the treatment of rheumatoid arthritis (RA). Hyperlipidemia has been reported to be one of the most common adverse effects of tocilizumab, however, the underlying mechanisms remain unknown. To understand lipid metabolism precisely, we measured plasma cytokines, small dense low-density lipoprotein (LDL), oxidized LDL and cholesterol level in each lipoprotein fraction using the high-performance liquid chromatography method before and after the tocilizumab treatment, and also studied the effect of rosuvastatin on tocilizumab-induced dyslipidemia in a diabetic patient complicated with RA. We found that rosuvastatin significantly ameliorated the tocilizumab-induced dyslipidemia.




J Endocrinol Metab. 2011;1(4):196-200
doi: https://doi.org/10.4021/jem51w


Keywords


Diabetes; Interleukin-6; Small dense low-density lipoprotein; Tocilizumab

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.